Wright Medical Group, Inc. (WMGI) recently received the Food and Drug administration (FDA) approval to market its CONSERVE Plus Total Hip Resurfacing System in the U.S. The new system, which has received FDA approval, provides surgeons with a bone-conserving alternative to traditional total hip replacement.
With the FDA approval, Wright Medical can now market CONSERVE Plus in the original femoral and acetabular component configuration in the U.S. as specified in its PreMarket Approval (PMA) application with the FDA. The company also intends to develop additional enhancements to the system. Wright Medical is already marketing its CONSERVE Plus system, which has received FDA approval, with additional features in the international markets.
The CONSERVE Plus system, which has received FDA approval, offers pain relief and restoration of normal hip functions while retaining maximum of the healthy bone. It preserves future surgery options, including a primary total hip replacement. It is seen that hip resurfacing is an ideal alternative option for young and active patients who are in need for hip reconstruction.
We think that the new product will be widely accepted by patients and surgeons. This will boost the company’s top-line. Wright Medical is a global orthopedic devices company specializing in the design, manufacture, and marketing of reconstructive joint devices and bio-orthopedic materials. The orthopedic industry is highly competitive, and Wright Medical faces challenges from large players, such as, Zimmer Holdings Inc. (ZMH), Stryker Corporation (SYK), Johnson & Johnson/De Puy (JNJ), Smith & Nephew plc. (SNN), and Biomet.
Read the full analyst report on “WMGI”
Read the full analyst report on “ZMH”
Read the full analyst report on “SYK”
Read the full analyst report on “JNJ”
Read the full analyst report on “SNN”
Zacks Investment Research
